Resveratrol: A new potential therapeutic agent for melanoma?

2019 ◽  
Vol 26 ◽  
Author(s):  
Mohamad Hossein Pourhanifeh ◽  
Kazem Abbaszadeh-Goudarzi ◽  
Mohammad Goodarzi ◽  
Sara G.M. Piccirillo ◽  
Alimohammad Shafiee ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Therapeutic Agent ◽  
Current Knowledge ◽  
Treatment Resistance ◽  
Anti Cancer ◽  
Apoptosis Inducer ◽  
Life Threatening ◽  
First Time

: Melanoma is the most life-threatening and aggressive class of skin malignancies. The incidence of melanoma has steadily increased. Metastatic melanoma is greatly resistant to standard anti-melanomatreatments such as chemotherapy, and 5-year survival rate of cases with melanoma who have metastatic form of disease is less than 10%. The contributing role of apoptosis, angiogenesis and autophagy in the pathophysiology of melanoma has been previously demonstrated. Thus, it is extremely urgent to search for complementary therapeutic approachesthat couldenhance the quality of life of subjects and reduce treatment resistance and adverse effects. Resveratrol, known as a polyphenol component present in grapes and some plants, has anti-cancer properties due to its function as an apoptosis inducer in tumor cells, and anti-angiogenic agent to prevent metastasis. However, more clinical trials should be conducted to prove resveratrol efficacy. : Herein, for first time, we summarize current knowledge of anti-cancerous activities of resveratrol in melanoma.

scholarly journals Therapy for myeloproliferative neoplasms: when, which agent, and how?

Hematology ◽  
2014 ◽  
Vol 2014 (1) ◽  
pp. 277-286 ◽  
Author(s):  
Holly L. Geyer ◽  
Ruben A. Mesa
Keyword(s):  
Quality Of Life ◽  
Disease Burden ◽  
Myeloproliferative Neoplasms ◽  
Jak Inhibitors ◽  
Symptom Profiles ◽  
Risk Of Progression ◽  
Life Threatening ◽  
Jak2 Inhibition

Abstract Myeloproliferative neoplasms, including polycythemia vera (PV), essential thrombocythemia, and myelofibrosis (MF) (both primary and secondary), are recognized for their burdensome symptom profiles, life-threatening complications, and risk of progression to acute leukemia. Recent advancements in our ability to diagnose and prognosticate these clonal malignancies have paralleled the development of MPN-targeted therapies that have had a significant impact on disease burden and quality of life. Ruxolitinib has shown success in alleviating the symptomatic burden, reducing splenomegaly and improving quality of life in patients with MF. The role and clinical expectations of JAK2 inhibition continues to expand to a variety of investigational arenas. Clinical trials for patients with MF focus on new JAK inhibitors with potentially less myelosuppression (pacritinib) or even activity for anemia (momelotinib). Further efforts focus on combination trials (including a JAK inhibitor base) or targeting new pathways (ie, telomerase). Similarly, therapy for PV continues to evolve with phase 3 trials investigating optimal frontline therapy (hydroxyurea or IFN) and second-line therapy for hydroxyurea-refractory or intolerant PV with JAK inhibitors. In this chapter, we review the evolving data and role of JAK inhibition (alone or in combination) in the management of patients with MPNs.

The role of patient-reported outcomes in outpatients receiving active anti-cancer treatment: impact on patients’ quality of life

2019 ◽  
Vol 27 (12) ◽  
pp. 4697-4704 ◽  
Author(s):  
Chiara Baratelli ◽  
Carmela Giovanna Cleopatra Turco ◽  
Gaetano Lacidogna ◽  
Elisa Sperti ◽  
Francesca Vignani ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Cancer Treatment ◽  
Patient Reported Outcomes ◽  
Patient Reported ◽  
Anti Cancer

scholarly journals Therapy for myeloproliferative neoplasms: when, which agent, and how?

Blood ◽  
2014 ◽  
Vol 124 (24) ◽  
pp. 3529-3537 ◽  
Author(s):  
Holly L. Geyer ◽  
Ruben A. Mesa
Keyword(s):  
Quality Of Life ◽  
Disease Burden ◽  
Myeloproliferative Neoplasms ◽  
Jak Inhibitors ◽  
Symptom Profiles ◽  
Risk Of Progression ◽  
Life Threatening ◽  
Jak2 Inhibition

Abstract Myeloproliferative neoplasms, including polycythemia vera (PV), essential thrombocythemia, and myelofibrosis (MF) (both primary and secondary), are recognized for their burdensome symptom profiles, life-threatening complications, and risk of progression to acute leukemia. Recent advancements in our ability to diagnose and prognosticate these clonal malignancies have paralleled the development of MPN-targeted therapies that have had a significant impact on disease burden and quality of life. Ruxolitinib has shown success in alleviating the symptomatic burden, reducing splenomegaly and improving quality of life in patients with MF. The role and clinical expectations of JAK2 inhibition continues to expand to a variety of investigational arenas. Clinical trials for patients with MF focus on new JAK inhibitors with potentially less myelosuppression (pacritinib) or even activity for anemia (momelotinib). Further efforts focus on combination trials (including a JAK inhibitor base) or targeting new pathways (ie, telomerase). Similarly, therapy for PV continues to evolve with phase 3 trials investigating optimal frontline therapy (hydroxyurea or IFN) and second-line therapy for hydroxyurea-refractory or intolerant PV with JAK inhibitors. In this chapter, we review the evolving data and role of JAK inhibition (alone or in combination) in the management of patients with MPNs.

scholarly journals New opportunities for treatment of severe bronchial asthma: from clinical studies to portraits of patients

2015 ◽  
Vol 12 (3) ◽  
pp. 51-61
Author(s):  
N M Nenasheva
Keyword(s):  
Quality Of Life ◽  
Severe Asthma ◽  
Bronchial Asthma ◽  
Significant Proportion ◽  
Poor Quality ◽  
New Class ◽  
Definition Of ◽  
First Time

The proportion of patients with controlled asthma has increased over the last 15 years, however, still there is a significant proportion of patients who do not achieve control of the disease, and therefore have a high risk of exacerbations, hospitalizations, and poor quality of life. Patients with severe asthma, for which there were limited additional pharmacotherapy are the major problem. For the first time in recent years in the treatment of asthma a new class of drugs appeared: longacting anticholinergics - tiotropium which had been entered in stepwise therapy of asthma by GINA 2015. The definition of severe asthma, the role of the cholinergic nervous system in bronchial asthma, mechanism of action and clinical efficacy of tiotropium in severe bronchial asthma adults are described in the article.

scholarly journals The Role of Curcumin in the Modulation of Ageing

2019 ◽  
Vol 20 (5) ◽  
pp. 1239 ◽  
Author(s):  
Anna Bielak-Zmijewska ◽  
Wioleta Grabowska ◽  
Agata Ciolko ◽  
Agnieszka Bojko ◽  
Grażyna Mosieniak ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Natural Products ◽  
Cellular Senescence ◽  
Current Knowledge ◽  
Model Organisms ◽  
Age Related ◽  
Daily Diet

It is believed that postponing ageing is more effective and less expensive than the treatment of particular age-related diseases. Compounds which could delay symptoms of ageing, especially natural products present in a daily diet, are intensively studied. One of them is curcumin. It causes the elongation of the lifespan of model organisms, alleviates ageing symptoms and postpones the progression of age-related diseases in which cellular senescence is directly involved. It has been demonstrated that the elimination of senescent cells significantly improves the quality of life of mice. There is a continuous search for compounds, named senolytic drugs, that selectively eliminate senescent cells from organisms. In this paper, we endeavor to review the current knowledge about the anti-ageing role of curcumin and discuss its senolytic potential.

PRINCIPLES OF SYNERGETIC APPROACH IN THE PSYCHOLOGICAL AND PEDAGOGICAL SUPPORT OF OPTIMIZATION OF THE QUALITY OF LIFE OF A PERSON WITH DISABILITIES

2019 ◽  
Vol 29 (2) ◽  
pp. 212-218
Author(s):  
V.Sh. Maslennikova ◽  
V.I. Aidarov
Keyword(s):  
Quality Of Life ◽  
Persons With Disabilities ◽  
Rehabilitation Process ◽  
Self Development ◽  
The Disabled ◽  
Methodological Approaches ◽  
First Time ◽  
Methods Of Treatment

The article reveals the role of synergetic approach to psychological and pedagogical support of optimization of the quality of life of a person with disabilities, acting as an integrator of methodological approaches of sociocentric and anthropocentric concepts. The synergetic approach allows us to consider psychological and pedagogical support for optimizing the quality of life of persons with disabilities as a process, largely self-organizing, not based on direct cause-and-effect relationships, and occurring ambiguously; the process due to a variety of internal and external influences; natural and random; predictable and natural, ordered and chaotic. For such elaborate system as the personality with disabilities we cannot impose compulsory methods of treatment. Therefore the process of psychological and pedagogical support for optimizing the quality of life of the personality with disabilities is based on the main principle - voluntariness. Especially it has to be observed when choosing methods and ways of rehabilitation actions and to be guided by regulated, but at the same time freedom of choice for the disabled person. Any elaborate system has, as a rule, not one but a set of its own, satisfying its nature, ways of development. Thus, psychological and pedagogical support of optimization of the quality of life of the personality with disabilities promotes self-expression, self-affirmation and self-development of the personality through the actions which are freely chosen, multidirectional, sometimes spontaneous and promote optimization of rehabilitation process. Using the ideas of synergetics, we tried to prove for the first time the process of psychological and pedagogical support for optimizing the quality of life of a person with disabilities in the conditions of medical stationary institution.

scholarly journals Pain with Life-Threatening Illness: Its Perception and Control Are Inextricably Linked with Quality of Life

2000 ◽  
Vol 5 (4) ◽  
pp. 271-275 ◽  
Author(s):  
S Robin Cohen ◽  
Balfour M Mount
Keyword(s):  
Quality Of Life ◽  
Pain Control ◽  
Essential Role ◽  
Pain Perception ◽  
Life Threatening Illness ◽  
Emotional Aspects ◽  
Life Threatening ◽  
And Control

This article describes how the quality of life of people with a life-threatening illness is affected by pain, and how their pain is influenced by all aspects of their quality of life. These aspects include the physical, psychological, cognitive, social, and spiritual and existential domains. This concept of pain is placed in the context of Ron Melzack's work highlighting the essential role of cognitive and emotional aspects of pain perception, and their influence on pain control. These issues continue to be a guiding force in the authors' own work and that of many others working in the field.

scholarly journals A Hypothesis on the Possible Potential of Plantago Major in the Treatment of Urticaria

2014 ◽  
Vol 3 (2) ◽  
pp. 123-126
Author(s):  
Mohammad Ali Yazdian ◽  
Mahmood Khodadoost ◽  
Mehdi Gheisari ◽  
Mohammad Kamalinejad ◽  
Amir Hooshang Ehsani
Keyword(s):  
Quality Of Life ◽  
Effective Properties ◽  
Current Knowledge ◽  
Hypersensitivity Reactions ◽  
Plantago Major ◽  
Herbal Therapy ◽  
Direct Role ◽  
Quality Of Life Index

Background:Urticaria is a skin disease characterized by pruritic edematous lesions also called wheals. Although these lesions are self-limited they may result in lowered quality of life index. By far, the most recognized mechanisms that trigger the progression of this condition are hypersensitivity reactions. As an herbal therapy, Plantago major has been named in several references of Persian traditional medicine with effective properties in ameliorating urticarial symptoms. In this study we aimed to investigate whether Plantago major has the potential to be used clinically in treatment of urticaria according to the current knowledge about the plant effects.Materials and Methods:A combination of “Plantago major” and other terms related to urticarial therapy such as “mast cell”, “anti-inflammatory”, “prostaglandin”, “histamine” and “IgE” that may have possible role in progression or suppression of urticaria was searched in Google Scholar and PubMed as the reference databases.Results:Eleven articles discussing either the direct role of Plantago major or any of its constituents in urticarial related bimolecular pathways were selected.Conclusion:Review of the selected articles indicated that Plantago major can effectively suppress many of hypersensitivity reactions which are also contributors in the pathophysiology of urticaria development. Further clinical trials are needed to prove the efficacy of this herbal treatment.

scholarly journals Quality of Life and Sexual Health in the Aging of PCa Survivors

2014 ◽  
Vol 2014 ◽  
pp. 1-16 ◽  
Author(s):  
Mauro Gacci ◽  
Elisabetta Baldi ◽  
Lara Tamburrino ◽  
Beatrice Detti ◽  
Lorenzo Livi ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Sexual Health ◽  
Negative Impact ◽  
Current Knowledge ◽  
Urinary Continence ◽  
Low Grade ◽  
Sexual Hormones ◽  
Male Population

Prostate cancer (PCa) is the most common malignancy in elderly men. The progressive ageing of the world male population will further increase the need for tailored assessment and treatment of PCa patients. The determinant role of androgens and sexual hormones for PCa growth and progression has been established. However, several trials on androgens and PCa are recently focused on urinary continence, quality of life, and sexual function, suggesting a new point of view on the whole endocrinological aspect of PCa. During aging, metabolic syndrome, including diabetes, hypertension, dyslipidemia, and central obesity, can be associated with a chronic, low-grade inflammation of the prostate and with changes in the sex steroid pathways. These factors may affect both the carcinogenesis processes and treatment outcomes of PCa. Any treatment for PCa can have a long-lasting negative impact on quality of life and sexual health, which should be assessed by validated self-reported questionnaires. In particular, sexual health, urinary continence, and bowel function can be worsened after prostatectomy, radiotherapy, or hormone treatment, mostly in the elderly population. In the present review we summarized the current knowledge on the role of hormones, metabolic features, and primary treatments for PCa on the quality of life and sexual health of elderly Pca survivors.

Sign in / Sign up

Export Citation Format

Share Document